

FORM PTO-1449  
(Rev. 2-32)

FEB 25 2008

U.S. Department of Commerce  
Patent and Trademark Office

Atty. Docket No.

Serial No.

04-585

10/502,510

PROPRIETARY  
INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT  
(Use several sheets if necessary)

Applicant:

Mohamed Raafat El-Gewely

Filing Date:

05/02/05

Group:

1614

### U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

### FOREIGN PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Country	Class	Subclass	Translation Yes No
/S.L./	WO 98/13513	04/02/1998	WO			
/S.L./	WO 00/11216	03/02/2000	WO			
/S.L./	<del>WO 97/27212</del>	07/31/1997	WO			

WO97/27212

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

/S.L./	Bullock, et al., Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy, Oncogene, 19:1245-1256(2000).
	Abarzua, et al., Restoration of the transcription activation function to mutant p53 in human cancer cells, Oncogene, 13:2477-2482(1996).
	Bullock, et al., Rescuing the Function of Mutant p53, Nature, 1:68-76 (2001).
	Anfinsen, C., Classical Protein Chemistry in a World of Slicing and Splicing, Protein Engineering, Applications in Science, Medicine and Industry, Academic Press, Inc., 3-13 (1986).
	Blin, N., et al., A general method for isolation of high molecular weight DNA from Eukaryotes, Nucleic Acids Research, 3:2303-2308 (1976).
	Colas, P., et al., Genetic selection of peptide aptamers that recognize and inhibit cyclin-dependent kinase 2, Nature, 380:548-550 (1996).
	El-Deiry, W.S., et al., WAF1, a potential mediator of p53 tumor suppression, Cell, 75:817-825 (1993).
	El-Gewely, M.R., Shorter is better, Nature Biotechnology, 17:210 (1999).
	Fenton, C., et al., Modulation of the Escherichia coli Tryptophan Repressor Protein by Engineered Peptides, Biochem. Biophys. Res. Commun. 242:71-78 (1998).
EXAMINER	DATE CONSIDERED 08/26/2008
/Sue Liu/	

FORM PTO-1449  
(Rev. 2-32)

U.S. Department of Commerce  
Patent and Trademark Office

Atty. Docket No.

04-585

Serial No.

10/502,510

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT  
(Use several sheets if necessary)

Applicant:

Mohamed Raafat El-Gewely

Filing Date:

05/02/05

Group:

1614

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

/S.L./	Fukazawa, T., et al, Differential involvement of the CD95 (Fas/APO-1) receptor/ligand system on apoptosis included by the wild-type p53 gene transfer in human cancer cells, Oncogene, 18:2189-2199 (1999).
	Gates, C.M., et al., Affinity Selective Isolation of Ligands from Peptide Libraries through Display on a lac Repressor "Headpiece Dimer", J. Mol. Biol., 255:373-386 (1996).
	Hanes, J., et al., In vitro selection and evolution of functional proteins by using ribosome display., Proc. Natl. Acad. Sci. USA, 94:4937-4942 (1997).
	Harayama, S., et al., Artificial evolution by DNA shuffling, Trends Biotechnol. 16:76-82 (1998).
	Hermeking, H., et al., 14-3-3 sigma is a p53-regulated inhibitor of G2/M progression, Mol. Cell., 1:3-11 (1997).
	Kim, A.L., et al., Conformational and Molecular Basis for Induction of Apoptosis by a p53 C-terminal Peptide in Human Cancer Cells, J. Biol. Chem. 274:34924-34931 (1999).
	Lowman, H.B., Bacteriophage Display and Discovery of Peptide Leads for Drug Development, Annu. Rev. Biophys Biol. Struct., 26:401-424 (1997).
	Parker, B.A., et al., Regulation of simian virus 40 transcription: sensitive analysis of the RNA species present early in infections by virus or viral DNA, J. Virol. 31:360-369 (1979).
	Sigal, A., et al., Oncogenic Mutations of the p53 Tumor Suppressor: The Demons of the Guardian of the Genome, Cancer Res., 60:6788-6793 (2000).
	Storbakk, N., et al., In vivo Interaction Between Mutated Tryptophan Repressors of Escherichia coli, Journal of Molecular Biology, 256:889-896(1996).
	Thornborrow, E.C., et al., One Mechanism for Cell Type-specific Regulation of the bax Promoter by the Tumor Suppressor p53 is Dictated by the p53 Response Element, J. Biol. Chem., 274:33747-33756 (1999).
	Varshavsky, A., The N-end rule pathway of protein degradation, Genes to Cells, 2:13-28 (1997).
	Vogelstein, B., et al., Surfing the p53 network, Nature, 408:307-310 (2000).
	Watanabe, T., et al., Induction of wild-type p53 activity in human cancer cells by ribozymes that repair mutant p53 transcripts, Proc. Natl. Acad. Sci., 97:8490-8494 (2000).
EXAMINER	/Sue Liu/
DATE CONSIDERED	08/26/2008

FORM PTO-1449  
(Rev. 2-32)

U.S. Department of Commerce  
Patent and Trademark Office

Atty. Docket No.

04-585

Serial No.

10/502,510

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
(Use several sheets if necessary)

**Applicant:**

Mohamed Raafat El-Gewely

**Filing Date:**

05/02/05

**Group:**

1614

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).**

/S.L./	Wolff, R.A., et al., <i>A rapid and easy method for DNA recovery from agarose gels using Wizard minicolumns</i> , Trends Genet, 12:339-340 (1996).		
	Xu, H., et al., <i>P53-responsive genes and the potential for cancer diagnostics and therapeutics development</i> . Biotechnology Annual Review, Elsevier Science B.V., 7:131-164 (2001).		
	Yu, J., et al., <i>Identification and classification of p53-regulated genes</i> , Proc. Natl. Acad. Sci. 96:14517-14522 (1999).		
	Famulok, M., et al., <i>Nucleic Acid Aptamers-From Selection in Vitro to Applications in vivo</i> , Acc. Chem. Res., 33:591-599 (2000).		
	Hermann, T., et al., <i>Adaptive Recognition by Nucleic Acid Aptamers</i> , Science, 287:820-825 (2000).		
	Hicke, B.J., et al., <i>Tenascin-C Aptamers Generated Using Tumor Cells and Purified Protein</i> , J. Biol. Chem., 276:48644-48654 (2001).		
	Hoppe-Seyler, F., et al., <i>Peptide aptamers: new tools to study protein interactions</i> , J. Steroid Biochem Mol. Biol., 78:105-111(2001).		
	Jayasena, S.D., <i>Aptamers: An Emerging Class of Molecules That Rival Antibodies in Diagnostics</i> , Clin Chem., 45:1628-1650 (1999).		
	Gold, et al., <i>From oligonucleotide shapes to genomic SELEX: Novel biological regulatory loops</i> , Proc. Natl. Acad. Sci., 94:59-64 (1997).		
↓	Ellington, et al., <i>Aptamers as potential nucleic acid pharmaceuticals</i> , Biotechnology Annual Review, Elsevier Science B.V., 1:185-214 (1995).		
EXAMINER	/Sue Liu/	DATE CONSIDERED	08/26/2008

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.